BUFFALO, N.Y., June 14, 2021 /PRNewswire/ -- Labcorp (NYSE: LH),
a leading global life sciences company, and OmniSeq, a
CAP-accredited, molecular diagnostic innovation of Roswell Park
Comprehensive Cancer Center, today announced the launch of OmniSeq
INSIGHT℠, a comprehensive genomic and immune profiling,
tissue-based test that integrates next-generation sequencing (NGS)
technology. The test is designed to advance precision oncology and
improve patient outcomes, as part of Labcorp's commitment to
empower better health decisions for patients through the addition
of cutting-edge diagnostic tools in precision medicine.
"There continues to be significant advancements in the oncology
space, including the identification of new biomarkers and therapies
at an unprecedented pace," said Prasanth
Reddy, M.D., MPH, senior vice president and oncology head at
Labcorp and a triple board-certified oncologist. "This new test
provides up-to-date, evidence-based treatment recommendations and
incorporates current guidelines into a report that is easy to
interpret, allowing clinicians to make the best treatment choices
for their patients, including potential clinical trials."
OmniSeq INSIGHT is a pan-cancer, solid tumor test that combines
two different treatment paradigms— genomic and immune profiling,
including tumor mutational burden, microsatellite instability, and
immune gene expression, which enhances the characterization of the
unique genomic biomarkers in a patient's tumor. The results from
the test are presented in an easy-to-read report, summarizing all
FDA-approved therapies and immunotherapies that match the patient's
tumor profile. This enables clinicians to provide the most
up-to-date treatments for their patients, in addition to
identifying clinical trials for which patients may be eligible
within 200 miles of their homes. The report provides evidence-based
recommendations specific to the individual test results through the
use of a proprietary database sourced from numerous biologic and
scientific literature, including National Comprehensive Cancer
Network (NCCN) guidelines®, giving clinicians access to the most
advanced treatment options.
OmniSeq INSIGHT is available to U.S.-based clinicians
exclusively through Labcorp, and across Canada through Dynacare, a Labcorp company.
The test is also available to global biopharmaceutical companies
through OmniSeq and Labcorp Drug Development. This can help reduce
development time and costs while maximizing patient stratification
by accelerating biomarker selection in preclinical and clinical
development and in targeted therapeutic and companion diagnostic
development.
OmniSeq and Labcorp Drug Development have a proven track record
of providing a range of solutions and can offer the scalability
required—backed by global expertise, regulatory guidance and
informatics systems that are tailored to the biopharmaceutical
partner's unique development needs.
"We are excited to advance our partnership with Labcorp,
continuing to provide increased access to oncology care for
patients leveraging Labcorp's extensive footprint and oncology
experience," said Margot Schoenborn,
CEO of OmniSeq. "We are making this test available globally to
biopharmaceutical customers for incorporation into their clinical
trials for biomarker stratification and to support new precision
medicine oncology approaches to drug and companion diagnostic
development."
OmniSeq INSIGHT is NYS CLEP
approved and leverages Labcorp's broad national coverage, including
in-network with most major health plans and 1,600 contractual
relationships with plans, payers and other health care
organizations.
For more information about OmniSeq INSIGHT, visit
omniseq.com/omniseq-insight/ and oncology.labcorp.com/omniseq.
About OmniSeq
OmniSeq, an innovation of Roswell Park
Comprehensive Cancer Center, is a CLIA, CAP accredited and ISO
13485:2016 certified molecular diagnostic laboratory based in
Buffalo, New York. OmniSeq
endeavors to find the right drug or the right trial for every
patient by improving access to better cancer treatment options
through molecular and immune profiling. For more information, call
+1-800-781-1259 or visit www.omniseq.com.
About Labcorp
Labcorp is a leading global life
sciences company that provides vital information to help doctors,
hospitals, pharmaceutical companies, researchers, and patients make
clear and confident decisions. Through our unparalleled diagnostics
and drug development capabilities, we provide insights and
accelerate innovations to improve health and improve lives. With
more than 70,000 employees, we serve clients in more than 100
countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn about Covance by
Labcorp at www.Covance.com, and Labcorp at www.Labcorp.com, or
follow us on LinkedIn and Twitter @Labcorp.
OmniSeq Contact:
Sawyer Lipari
slipari@lambert.com
Labcorp Contact:
Media: Christopher Allman-Bradshaw –
336-436-8263
Media@Labcorp.com
Investors: Chas Cook –
336-436-5076
Investor@Labcorp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/labcorp-and-omniseq-launch-insight-next-generation-sequencing-platform-to-advance-precision-oncology-301311676.html
SOURCE OmniSeq